Healthcare · Biotechnology
Price
$1.42
Market Cap
$844,772
Employees
5
Beta
1.10
Avg Volume
3,913,869
CEO
Joseph Edward Tucker
Business Description
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Business History
Price Overview
Last updated: Jun 27, 2026 10:08am (just now)$1.42
+0.14 (+10.55%)
Day Range
$1.27 – $1.46
52-Week Range
$1.26 – $17.64
50-Day MA
$2.52
200-Day MA
$4.30
Volume
198,258.00
Share Structure
Outstanding
597,012.00
Float
545,871.00
Free Float
91.4%
High free float
— 91.4% of shares trade freely, ~8.6% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Small absolute float (0.5M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.04
Stock Price: $1.42
EPS (Diluted): -36.24
EPS (Diluted): -36.24
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.29
Stock Price: $1.42
Total Equity: $4.18M
Shares: 334,719
Total Equity: $4.18M
Shares: 334,719
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
0.50
Market Cap: $844,772
Total Debt: $0.00
Cash: $4.68M
EBITDA: -$8.57M
Total Debt: $0.00
Cash: $4.68M
EBITDA: -$8.57M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
-$3.5M
Market Cap: $844,772
Total Debt: $0.00
Cash: $4.68M
Total Debt: $0.00
Cash: $4.68M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $1.42
Revenue: $0.00
Shares: 334,719
Revenue: $0.00
Shares: 334,719
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$200,858
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$8.77M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$12.13M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-221.0%
Net Income: -$12.13M
Total Equity: $4.18M
Total Equity: $4.18M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-162.4%
Operating Income: -$8.77M
Tax Rate: -38.3%
Equity: $4.18M
Total Debt: $0.00
Cash: $4.68M
Tax Rate: -38.3%
Equity: $4.18M
Total Debt: $0.00
Cash: $4.68M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
5.38
Current Assets: $4.94M
Current Liabilities: $918,400
Current Liabilities: $918,400
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $4.18M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $4.18M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 334,719
Shares: 334,719
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$12.48
Total Equity: $4.18M
Shares: 334,719
Shares: 334,719
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-24.32
Operating CF: -$8.14M
CapEx: $0.00
Shares: 334,719
CapEx: $0.00
Shares: 334,719
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.42
Stock Price: $1.42
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$12.13M
Net Income: -$12.13M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares ENVB against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 23, 2026 1:16am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $681,612 | $435,201 | $408,030 | $337,489 | $200,858 |
| Gross Profit | $-681,612 | $-435,201 | $-408,030 | $-337,489 | $-200,858 |
| Operating Expenses | $25.3M | $19.5M | $16.0M | $9.3M | $8.6M |
| Operating Income | -$25.9M | -$20.0M | -$16.4M | -$9.6M | -$8.8M |
| Net Income | -$49.0M | -$18.5M | $-17,292 | -$9.6M | -$12.1M |
| EBITDA | -$55.7M | -$19.5M | -$16.9M | -$9.2M | -$8.6M |
| EPS | $-1,244.28 | $-87.72 | $-97.08 | $-228.48 | $-36.24 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 23, 2026 1:16am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $17.4M | $17.7M | $2.3M | $2.2M | $4.7M |
| Total Current Assets | $17.7M | $18.4M | $3.6M | $2.7M | $4.9M |
| Total Assets | $26.7M | $19.6M | $4.3M | $3.1M | $5.1M |
| Current Liabilities | $2.1M | $4.0M | $2.3M | $1.5M | $918,400 |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.4M | $4.0M | $2.3M | $1.5M | $918,400 |
| Total Equity | $22.3M | $14.7M | $2.0M | $1.6M | $4.2M |
| Retained Earnings | -$60.7M | -$79.2M | -$96.5M | -$106.1M | -$114.8M |
Cash Flow (Annual)
Last updated: Jun 23, 2026 1:16am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$11.5M | -$17.1M | -$14.1M | -$7.7M | -$8.1M |
| Capital Expenditure | $-864,719 | $-584,165 | $-5,180 | $0 | $0 |
| Free Cash Flow | -$12.3M | -$17.7M | -$14.1M | -$7.7M | -$8.1M |
| Acquisitions (net) | $3.1M | $958,038 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | -$1.1M | $1.1M | $0 |
| Net Change in Cash | $15.8M | $367,885 | -$15.4M | $-46,951 | $2.4M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 10:08am (just now)| Metric | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Revenue |
$10.0M $10.0M – $10.0M
|
$10.0M $10.0M – $10.0M
|
$15.0M $15.0M – $15.0M
|
$25.0M $25.0M – $25.0M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$51.8M -$51.8M – -$51.8M
|
-$105.4M -$105.4M – -$105.4M
|
-$37.4M -$37.4M – -$37.4M
|
-$14.5M -$14.5M – -$14.5M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 23, 2026 1:16am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | +36.2% | +6.2% | +17.3% | +40.5% |
| Operating Income Growth | +23.1% | +17.6% | +41.4% | +8.9% |
| Net Income Growth | +62.2% | +99.9% | -55,273.2% | -26.7% |
| EBITDA Growth | +65.0% | +13.6% | +45.2% | +7.1% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2025-12-23 | DeWitt Sheila | A-Award | 7,633.00 | $0.00 | $0 |
| 2025-12-23 | Kegler George A. | A-Award | 7,633.00 | $0.00 | $0 |
| 2025-12-23 | PASQUALONE FRANK | A-Award | 7,633.00 | $0.00 | $0 |
| 2025-12-23 | Schabacker Marcus | A-Award | 7,633.00 | $0.00 | $0 |
| 2025-12-23 | Tucker Joseph Edward | A-Award | 60,296.00 | $0.00 | $0 |
| 2025-12-23 | WEBB MICHAEL D | A-Award | 7,633.00 | $0.00 | $0 |
| 2025-12-23 | Coveney Kevin Michael | A-Award | 40,198.00 | $0.00 | $0 |
| 2025-05-08 | Coveney Kevin Michael | A-Award | 74,150.00 | $0.00 | $0 |
| 2025-05-08 | Facchini Peter J. | A-Award | 24,717.00 | $0.00 | $0 |
| 2025-05-08 | Tucker Joseph Edward | A-Award | 98,866.00 | $0.00 | $0 |
| 2024-10-09 | DeWitt Sheila | A-Award | 27,845.00 | $0.00 | $0 |
| 2024-10-09 | Kegler George A. | A-Award | 47,733.00 | $0.00 | $0 |
| 2024-10-09 | Schabacker Marcus | A-Award | 47,733.00 | $0.00 | $0 |
| 2024-10-09 | WEBB MICHAEL D | A-Award | 47,733.00 | $0.00 | $0 |
| 2024-10-09 | PASQUALONE FRANK | A-Award | 47,733.00 | $0.00 | $0 |
| 2024-10-09 | Tucker Joseph Edward | A-Award | 161,633.00 | $0.00 | $0 |
| 2024-10-09 | Facchini Peter J. | A-Award | 40,000.00 | $0.00 | $0 |
| 2024-10-09 | Coveney Kevin Michael | A-Award | 100,000.00 | $0.00 | $0 |
| 2024-05-28 | DeWitt Sheila | 0.00 | $0.00 | $0 | |
| 2024-02-22 | Tucker Joseph Edward | A-Award | 100,000.00 | $0.00 | $0 |
Dividend History (Last 20)
Last updated: Jun 23, 2026 1:16am (4d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2008-04-23 | $0.02 | 2008-04-07 | 2008-04-15 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ENVB — it's generated by the pipeline (
market-narrative step).
No community reviews yet for ENVB.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30